Telmisartan Inhibits Non-Small Cell Lung Cancer by Inducing Ferroptosis through the NRF2/GPX4 Signaling Axis.

Ling-Jie Wang; Pengfei Guo; Sai Wang; Yizhao Chen; Hongwang Yan; Xue-Lin Zhang

doi:10.2174/0109298673422337251024103233

January 9, 2026

Telmisartan Inhibits Non-Small Cell Lung Cancer by Inducing Ferroptosis through the NRF2/GPX4 Signaling Axis.

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to explore the inhibitory effects of telmisartan on non-small cell lung cancer through ferroptosis induction.
Examined the effect of telmisartan on NSCLC cell lines
Analyzed the NRF2/GPX4 signaling pathway
Monitored indicators of cellular ferroptosis
Telmisartan significantly inhibited NSCLC cell growth
Induction of ferroptosis was confirmed
NRF2/GPX4 axis was activated during treatment

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Telmisartan inhibits non-small cell lung cancer by inducing ferroptosis, suggesting a new therapy approach.

Abstract

Telmisartan inhibited NSCLC by inducing ferroptosis via the NRF2/GPX4 axis, offering a new therapeutic strategy and potential clinical application for NSCLC treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/697462b5244d6b1945963eda https://doi.org/10.2174/0109298673422337251024103233

View at Publisher

Ask AI

Bookmark

Share

Telmisartan Inhibits Non-Small Cell Lung Cancer by Inducing Ferroptosis through the NRF2/GPX4 Signaling Axis.

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Telmisartan Inhibits Non-Small Cell Lung Cancer by Inducing Ferroptosis through the NRF2/GPX4 Signaling Axis.

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading